發(fā)布時(shí)間：2018-04-30 15:53

  本文選題：帕金森 + 普拉克索��； 參考：《山東醫(yī)藥》2017年42期

【摘要】：目的觀察多巴胺受體激動(dòng)劑普拉克索聯(lián)合美多芭治療帕金森病的臨床療效。方法將78例帕金森病患者隨機(jī)分為兩組各49例,對(duì)照組口服美多芭62.5 mg/次,3次/d,4周后增加為125 mg/次,每6 h服用1次;觀察組在對(duì)照組基礎(chǔ)上口服普拉克索0.125 mg/次,2次/d,4周可增加至0.25 mg/次,3次/d;共治療12周。治療12周后評(píng)價(jià)臨床療效,采用帕金森病統(tǒng)一評(píng)分量表(UPDRS)分別評(píng)價(jià)治療前及治療第8、12周時(shí)的日常生活能力(UPDRSⅡ)、運(yùn)動(dòng)障礙(UPDRSⅢ)及并發(fā)癥(UPDRSⅣ),記錄治療期間不良反應(yīng)發(fā)生情況。結(jié)果觀察組臨床療效優(yōu)良率為87.18%,高于對(duì)照組的58.97%(P0.05)。治療前,兩組UPDRSⅡ、UPDRSⅢ及UPDRSⅣ評(píng)分比較,差異無(wú)統(tǒng)計(jì)學(xué)意義;兩組治療第8、12周各項(xiàng)評(píng)分均較治療前下降(P均0.05),治療第12周各項(xiàng)評(píng)分低于治療第8周(P均0.05),且觀察組治療第8、12周各項(xiàng)評(píng)分低于對(duì)照組(P均0.05)。觀察組治療期間不良反應(yīng)發(fā)生率為10.26%,低于對(duì)照組的30.77%(P0.05)。結(jié)論普拉克索聯(lián)合美多芭治療帕金森病,有利于改善患者運(yùn)動(dòng)功能障礙及日常生活能力,同時(shí)減少并發(fā)癥及不良反應(yīng),從而提高臨床療效。
[Abstract]:Objective to observe the clinical effect of dopamine receptor agonist Praxol combined with medoba in the treatment of Parkinson's disease. Methods Seventy-eight patients with Parkinson's disease were randomly divided into two groups: the control group (n = 49) was treated with medopa 62.5 mg/ for 3 times / d for 4 weeks, which was taken once every 6 hours. On the basis of the control group, oral Praxol 0.125 mg/ / d for 4 weeks increased to 0. 25 mg/ / 3 / d for 12 weeks. The clinical effect was evaluated after 12 weeks of treatment. PD RS was used to evaluate ADL 鈪，

本文編號(hào)：1825180